Exceptional GMP flexibilities for medicines imported from third countries during the coronavirus (COVID-19) outbreak

'The document provides guidance on implementing flexibilities in good distribution practice (GDP) for medicines during the COVID-19 outbreak. It outlines principles for handling unexpected deviations, relying on information from third parties, and re-testing on importation. The guidance allows Qualified Persons to use professional judgement to decide whether certain actions are necessary, with a focus on maintaining supply in the interest of public health.'